Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization

Aim. To evaluate prediction role of the biomarkers soluble ST2 (sST2) and natriuretic hormone N-terminal propeptide (NT-proBNP) in risk assessment of adverse cardiovascular events (ACVE) in coronary heart disease patients (CHD) with chronic heart failure (CHF) after myocardial revascularization.

Material and methods. Totally, 87 patients included (72 males) with CHD and CHF I-III functional class by NYHA with ejection fraction of the left ventricle (LVEF) 63 [55; 65]%, mean age 63 [57; 69] y.o. Levels of sST2 and NT-proBNP in plasma were measured by immune enzyme assay before myocardial revascularization.

Results. In 12 months of prospective follow-up, patients were selected to 2 groups according to clinical course of CHF. To the group I the patients included (n=35) with ACVE, group II (b=52) — with none. It was found that in the group I the level of sST2 was higher by 41,5% (p<0,001) and reached 46,78 [37,88; 64,96] ng/mL, and in the group II — 27,39 [23,02; 35,4] ng/mL. Concentration of NT-proBNP in the group with ACVE was 2,5 times (p=0,004) higher comparing with group II and reached 189,21 [74,46; 580,79] and 73,58 [26,64; 155,77] pg/mL, respectively. In ROC-analysis it was found that the level of sST2  ≥34,18 ng/mL (sensitivity — 90,6%, specificity — 75,0%, AUC — 0,88, р<0,0001) and level of NT-proBNP  ≥276,96 pg/mL (sensitivity — 88,4%, specificity — 43,7%, AUC — 0,64, р<0,004) can be regarded as markers of ACVE during 12 months in CHD and CHF patients after revascularization. Also, together these two markers increase predictive significance of the analysis (sensitivity — 92,6%, specificity — 77,1%, AUC — 0,90, р<0,0001).

Conclusion. Therefore, the preprocedural level of sST2 can be regarded as non-invasive marker for prediction of ACVE. Combination of sST2 and NT-proBNP shows higher diagnostic sensitvity and specificity for prediction of adverse CHF course.

1. Shalnova SA, Deev AD. OSCAR Study lessons — “Epidemiology and treatment of highrisk patients in realworld Clinical practice, 20052006”. Cardiovascular Therapy and Prevention. 2007;6(1):47-53. (In Russ.)

2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.

3. Teplyakov AT, Grakova EV, Berezikova EN, et al. Early markers of progression of heart failure and apoptosis: their role in predicting the risk of adverse cardiovascular events in patients with prior myocardial infarction. Bulletin of Siberian Medicine. 2016;15(1):37-46. (In Russ.) doi:10.20538/1682-0363-2016-1-37-46.

4. Schmitz J, Owyang A, Oldham E, et al. Il-33, and interleukin1-like cytokine that signals via the Il-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90. doi:10.1016/j.immuni.2005.09.015.

5. Kakkar R, Lee RT. The IL33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827-40. doi:10.1038/nrd2660.

6. Braunwald E. Biomarkers in heart failure. New Engl J Med. 2008;358:2148-59. doi:10.1056/NEJMra0800239.

7. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST elevation myocardial infarction. Circulation. 2008;117:1936-44. doi:10.1161/CIRCULATIONAHA.107.728022.

8. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-90. doi: 10.1161/01.CIR.0000127958.21003.5A.

9. Demyanets S, Speidl SW, Tentzeris I, et al. Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome. Ed. Ingo Ahrens. PLoS ONE 2014;9.4:e95055. PMC. Web. 21 Apr.2014. doi:10.1371/journal.pone.0095055.

10. Tsapaki A, Zaravinos A, Apostolakis S, et al. Genetic variability of the distal promoter of the ST2 gene is associated with angiographic severity of coronary artery disease. J Thromb Thrombolysis. 2010; 30:365-71. doi:10.1007/s11239-010-0496-y.

11. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. JACC. 2008;52(18):1458-65. doi:10.1016/j.jacc.2008.07.042.

12. Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009;2:311-9. doi:10.1161/CIRCHEARTFAILURE.108.833707.

13. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. JACC. 2007;50(7):607-13. doi:10.1016/j.jacc.2007.05.014.

14. Wojtczak-Soska K, Pietrucha T, Sakowicz, et al. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Archives of Medical Science: AMS. 2013;9(1):21-6. doi:10.5114/aoms.2013.33344.

15. Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts longterm mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2014;60(3):530-40. doi:10.1373/clinchem.2013.209858.